Skip to main content

Beneficial ownership — 13D / 13G

87,314 recent Schedule 13D / 13G filings — activist (13D) and passive (13G) stakes above 5% of a class.

Reporting person Issuer Schedule % of class Filed
William J. Weber CLDI Calidi Biotherapeutics, Inc. 13G/A 1% 2y
EcoR1 Capital, LLC TPST Tempest Therapeutics, Inc. 13G/A 0% 2y
Lincoln Park Capital Fund, LLC ENSC Ensysce Biosciences, Inc. 13G/A 3.79% 2y
Fourthstone LLC FNRN First Northern Community Bancorp 13G 6.29% 2y
Lighthouse Investment Partners, LLC FRLA Fortune Rise Acquisition Corporation Class A Common Stock 13G 5.19% 2y
Empyrean Capital Partners, LP CCVI Churchill Capital Corp VI 13G/A 0% 2y
DISCIPLINED GROWTH INVESTORS INC /MN GEOS Geospace Technologies Corp 13G/A 11.19% 2y
Hillhouse Investment Management, Ltd. GOSS Gossamer Bio, Inc. 13G/A 2.2% 2y
ARMISTICE CAPITAL, LLC VIVO VivoPower PLC 13G/A 4.99% 2y
Robert W. Humphreys DLA Delta Apparel Inc. 13G/A 6.7% 2y
SoftVest Advisors, LLC PBT Permian Basin Royalty Trust 13G/A 8.9% 2y
SNYDER CAPITAL MANAGEMENT L P OPLN OPENLANE, Inc. 13G/A 3.77% 2y
ArrowMark Colorado Holdings LLC ANGI Angi Inc. 13G 5.99% 2y
Sculptor Capital LP SBXC SilverBox Corp III 13G/A 0% 2y
Westchester Capital Management, LLC ROSS Ross Acquisition Corp II 13G 9.82% 2y
Fourthstone LLC ISTR Investar Holding Corp 13G/A 9.97% 2y
Nantahala Capital Management, LLC SLNO Soleno Therapeutics Inc 13G/A 9.9% 2y
PAULSON & CO. INC. MDGL Madrigal Pharmaceuticals, Inc. 13G/A 5.6% 2y
PRICE T ROWE ASSOCIATES INC /MD/ SUM Summit Materials, Inc. Class A Common Stock 13G/A 7.4% 2y
RTW INVESTMENTS, LP ACAD Acadia Pharmaceuticals Inc 13G 6.9% 2y
RA CAPITAL MANAGEMENT, L.P. RXST RxSight, Inc. 13G/A 9.5% 2y
Aman Narang TOST Toast, Inc. 13G/A 5.2% 2y
DISCIPLINED GROWTH INVESTORS INC /MN PRLB Proto Labs Inc 13G/A 6.74% 2y
Ares Trading SA VERA Vera Therapeutics, Inc. 13G/A 3.6% 2y
RTW INVESTMENTS, LP VCEL Vericel Corp 13G/A 6.7% 2y
TANG CAPITAL MANAGEMENT, LLC ALT Altimmune, Inc. 13G/A 5.1% 2y
Driehaus Capital Management LLC AAOI Applied Optoelectronics, Inc. 13G 7.78% 2y
MASON CAPITAL MANAGEMENT LLC ATS ATS Corp 13G 18.5% 2y
GREAT POINT PARTNERS LLC URGN UroGen Pharma Ltd. 13G/A 8.49% 2y
Fourthstone LLC SSBK Southern States Bancshares, Inc. Common 13G/A 0% 2y
Paradigm Biocapital Advisors LP AMAM Ambrx Biopharma, Inc. Common Stock 13G/A 7.1% 2y
CVI Investments, Inc. DUET DUET Acquisition Corp. Class A Common Stock 13G/A 0% 2y
Klaus Schauser APPF Appfolio Inc 13G/A 15.1% 2y
Atlas Merchant Capital LLC DUET DUET Acquisition Corp. Class A Common Stock 13G/A 0% 2y
Venrock Healthcare Capital Partners III, L.P. SYRE Spyre Therapeutics, Inc. 13G/A 9.99% 2y
Newtyn Management, LLC BVFL BV Financial, Inc. 13G 8.8% 2y
CVI Investments, Inc. SIDU Sidus Space Inc. 13G/A 0% 2y
FIR TREE CAPITAL MANAGEMENT LP PFSA Profusa, Inc. 13G/A 0% 2y
Boundary Creek Advisors LP MATV Mativ Holdings, Inc. 13G 7% 2y
METEORA CAPITAL, LLC ADOC Edoc Acquisition Corp. Class A Ordinary Share 13G/A 6.99% 2y
BIOTECHNOLOGY VALUE FUND L P VSTM Verastem, Inc. 13G/A 9.99% 2y
Antara Capital LP KRNL Kernel Group Holdings, Inc. Class A Ordinary Shares 13G 7.2% 2y
T. Rowe Price Investment Management, Inc. IR Ingersoll Rand Inc. 13G/A 8.3% 2y
VIKING GLOBAL INVESTORS LP PHVS Pharvaris N.V. 13G/A 7% 2y
PRICE T ROWE ASSOCIATES INC /MD/ AEE Ameren Corp 13G/A 7% 2y
ADW Capital Partners, L.P. RICK Rci Hospitality Holdings, Inc. 13G/A 9.9% 2y
Select Equity Group, L.P. MIDD MIDDLEBY Corp 13G/A 9.2% 2y
HGC Investment Management Inc. ISRLF Israel Acquisitions Corp 13G 5.22% 2y
Jefferies Financial Group Inc. HLMN Hillman Solutions Corp. 13G/A 5.1% 2y
Deer Park Road Management Company, LP ONIT Onity Group Inc. 13G/A 7.53% 2y